about
Evidence for X-chromosomal schizophrenia associated with microRNA alterationsMissense mutations in the MEFV gene are associated with fibromyalgia syndrome and correlate with elevated IL-1beta plasma levelsRandomized phase II trial of concurrent versus sequential bortezomib plus docetaxel in advanced non-small-cell lung cancer: a California cancer consortium trial.Functional comparison of T cells recognizing cytomegalovirus pp65 and intermediate-early antigen polypeptides in hematopoietic stem-cell transplant and solid organ transplant recipients.Phase II trial of intraperitoneal cisplatin with intravenous doxorubicin and cyclophosphamide in previously untreated patients with advanced ovarian cancer-long-term follow-up.CCI-779 in metastatic melanoma: a phase II trial of the California Cancer Consortium.Toxicity equivalence range design (TEQR): a practical Phase I design.Three ways of combining genotyping and resequencing in case-control association studies.Gender influences herpes simplex virus type 1 infection in normal and gamma interferon-mutant micePrimary response against cytomegalovirus during antiviral prophylaxis with valganciclovir, in solid organ transplant recipientsComplexity and power in case-control association studies.Phase II study of Cediranib (AZD 2171), an inhibitor of the vascular endothelial growth factor receptor, for second-line therapy of small cell lung cancer (National Cancer Institute #7097).First-in-human phase 1/2a trial of CRLX101, a cyclodextrin-containing polymer-camptothecin nanopharmaceutical in patients with advanced solid tumor malignanciesTissue-specific time courses of spontaneous mutation frequency and deviations in mutation pattern are observed in middle to late adulthood in Big Blue mice.Vaccine-induced control of viral shedding following rhesus cytomegalovirus challenge in rhesus macaques.Discovery of potential new gene variants and inflammatory cytokine associations with fibromyalgia syndrome by whole exome sequencing.Manganese superoxide dismutase-mediated gene expression in radiation-induced adaptive responsesCharacterization of immunologic properties of a second HLA-A2 epitope from a granule protease in CML patients and HLA-A2 transgenic miceBortezomib for patients with advanced-stage bronchioloalveolar carcinoma: a California Cancer Consortium Phase II study (NCI 7003).A phase II trial of the Src-kinase inhibitor AZD0530 in patients with advanced castration-resistant prostate cancer: a California Cancer Consortium study.A phase I and pharmacokinetic study of oral 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) in the treatment of advanced-stage solid cancers: a California Cancer Consortium Study.Clinical evaluation of safety and immunogenicity of PADRE-cytomegalovirus (CMV) and tetanus-CMV fusion peptide vaccines with or without PF03512676 adjuvant.A vaccine based on the rhesus cytomegalovirus UL128 complex induces broadly neutralizing antibodies in rhesus macaques.Loss of T cell progenitor checkpoint control underlies leukemia initiation in Rag1-deficient nonobese diabetic mice.Recombinant modified vaccinia virus Ankara expressing a soluble form of glycoprotein B causes durable immunity and neutralizing antibodies against multiple strains of human cytomegalovirus.Mamu-A01/K(b) transgenic and MHC Class I knockout mice as a tool for HIV vaccine development.Impact of donor CMV status on viral infection and reconstitution of multifunction CMV-specific T cells in CMV-positive transplant recipients.Identification of high risk DISC1 protein structural variants in patients with bipolar spectrum disorder.In vitro expansion of polyclonal T-cell subsets for adoptive immunotherapy by recombinant modified vaccinia Ankara.Two distinct pathways of immuno-modulation improve potency of p53 immunization in rejecting established tumors.Attenuated poxviruses generate clinically relevant frequencies of CMV-specific T cells.Trastuzumab plus docetaxel in HER-2/neu-positive prostate carcinoma: final results from the California Cancer Consortium Screening and Phase II Trial.Radioiodinated versus radiometal-labeled anti-carcinoembryonic antigen single-chain Fv-Fc antibody fragments: optimal pharmacokinetics for therapy.A randomized phase II trial of the matrix metalloproteinase inhibitor BMS-275291 in hormone-refractory prostate cancer patients with bone metastases.The cyclin-dependent kinase inhibitor UCN-01 plus cisplatin in advanced solid tumors: a California cancer consortium phase I pharmacokinetic and molecular correlative trial.Spontaneous mutation in Big Blue mice from fetus to old age: tissue-specific time courses of mutation frequency but similar mutation types.Induction of CTL response by a minimal epitope vaccine in HLA A*0201/DR1 transgenic mice: dependence on HLA class II restricted T(H) response.Speed congenics: a classic technique in the fast lane (relatively speaking).Phase II trial of combination intraperitoneal cisplatin and 5-fluorouracil in previously treated patients with advanced ovarian cancer: long-term follow-up.Ventricular rate control in chronic atrial fibrillation during daily activity and programmed exercise: a crossover open-label study of five drug regimens.
P50
Q21562396-463611ED-57B7-454A-9C57-534955D7349CQ24293495-D4E6989E-AA4E-4CAA-9131-6546F560967DQ33159653-F9B9C1FC-5AAE-4B95-A8D3-DF8A40ED4592Q33260989-C5FF784A-9FA7-4206-894C-5120243BE0A1Q33330934-777F2577-E872-4E38-B595-3681A793F3C9Q33367168-8FAEE4EA-6261-4322-849A-56B4C3ECE5A6Q33711091-F4375406-7598-4A7B-8313-F410C265A365Q33781083-DF72D120-BA06-4B42-9717-E5ED2B7048BEQ33866427-862CF746-DE19-484E-9978-69439FF28D0AQ33932079-F3902E54-6317-408E-B858-4720E8C9CA67Q34020703-C7D7F29D-0276-4BBE-BE41-9939F7419E50Q34026037-C8235FC6-149D-4ADB-9DAE-1D0318A978E1Q34327123-D3C1AB6F-73AE-44AE-93A3-04A4AEF5265CQ34390778-AA0894C3-7182-4555-A65B-69237039DC12Q34742892-060133F1-9458-4779-8EC4-5AB51ABCC0E2Q34769585-7A174A7B-6BA6-4687-B62D-1AB70B9CD488Q34784364-A3BD74A2-3D03-4EBC-9850-71091E1EE0E7Q35182714-7070D0F9-E2B2-4F70-9871-C988F1D013B6Q35561508-6D084BBB-032C-4D61-9260-45E9B0E2DEFEQ35576853-DCF7DABD-ABA1-4F20-B475-A7C6634B0B73Q35782691-A03B51CF-1AB6-4757-A59B-8DE240ADB822Q35842287-23254813-7D87-43CA-BC00-0CC40A90517CQ36559845-589D92F9-FB86-4BA1-94A6-1980F18BB614Q36717799-EBBA1E09-A0F8-40AD-B816-D4DF6350F218Q37093594-185972ED-F200-46C6-9175-B3241717CFFBQ37155744-5B6641F3-1D3C-4ED6-BA7B-96058DD5C8E9Q37262446-3EF9818A-B06D-42D8-875C-EF074BD227A8Q37789946-B6D6C4E4-3526-4BB0-94DE-A4E8787B7E49Q38314703-297CDD77-B910-4BF5-8922-EB482D9927E5Q38338244-23FDD440-A811-4258-B146-BBCC8CB4C388Q38342331-F6741DEA-E108-41B1-9288-9E296612B7FCQ38447818-51E5B36B-D3BA-4581-B2B6-B61719006740Q40181658-2B428E6C-FC33-4B0B-A13E-C426B27F2F36Q40343416-726B836E-2409-4954-A14D-52C58CF2E4F1Q40408817-12C2CDD0-B00B-45F7-9E0A-809B8F3C4FFAQ40528537-CC901973-5DBE-49B6-B313-0544FE3A6732Q40855997-AB495A8A-A7CB-4BD6-8BF5-DD4ACA8CF72AQ41632964-8B1A69B8-6010-4CC0-A0A0-8BEF2AAC3B63Q41738409-27D14B33-9C13-4338-B49E-96A95970C8C0Q42691907-83A2FA50-70B9-4E9D-91BF-FA6030247124
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Jeff Longmate
@ast
Jeff Longmate
@en
Jeff Longmate
@es
Jeff Longmate
@fr
Jeff Longmate
@nl
Jeff Longmate
@sl
type
label
Jeff Longmate
@ast
Jeff Longmate
@en
Jeff Longmate
@es
Jeff Longmate
@fr
Jeff Longmate
@nl
Jeff Longmate
@sl
altLabel
Jeff Longmate
@en
Jeffrey Allan Longmate
@en
prefLabel
Jeff Longmate
@ast
Jeff Longmate
@en
Jeff Longmate
@es
Jeff Longmate
@fr
Jeff Longmate
@nl
Jeff Longmate
@sl
P106
P1153
7004426675
P21
P31
P496
0000-0002-0869-7928